Inmune Bio

XPro1595 is a next-generation, selective tumor necrosis factor (TNF) inhibitor that targets soluble TNF while sparing transmembrane TNF. The company is evaluating it in Phase 2 trials for Alzheimer's disease and treatment-resistant depression, aiming to reduce neuroinflammation, a core driver of these conditions.

Unlike anti-amyloid antibodies that clear plaque build-up, Inmune Bio targets neuroinflammation via soluble TNF neutralization. The scientific premise posits that chronic immune dysfunction within the brain contributes directly to the synaptic loss and cognitive decline seen in Alzheimer's, a hypothesis not addressed by current FDA-approved monoclonal antibodies.

Yes. The XPro1595 platform is also being studied in treatment-resistant depression. Additionally, the company is developing INKmune, a biologic natural killer cell therapy designed to target both hematologic malignancies and solid tumors, providing a separate immuno-oncology pipeline.

XPro1595 is a dominant-negative TNF biologic — it works by selectively neutralizing soluble TNF, the form that drives chronic inflammation, without affecting transmembrane TNF, which is essential for immune surveillance and neuronal function. This selectivity is designed to maximize anti-inflammatory benefit while limiting immunosuppressive side effects common with broader TNF blockers.

No. Despite being categorized variably in external databases, Inmune Bio is a publicly traded biotechnology company. It does not manage a portfolio of external investments or function as a wealth-preservation structure; it is a drug development firm funded through equity financing to advance its clinical programs.